ArticleCancer reports (Hoboken, N.J.)2022

A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.

Jacqueline M Kraveka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.